http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002028823-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 |
| filingDate | 1999-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6395807bf34ac1d51c27351a9253e01b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18210893b91dbfa51fe469bfc4fc4fb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7ea9b47f98ee169efd17dd80f176f89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf77c3e34ab8f1d96d6afee9252d450 |
| publicationDate | 2002-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002028823-A1 |
| titleOfInvention | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| abstract | Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: n n n Each X, Y and Z are independently selected from a member of the group consisting of C(R 3 ), N, N(R 3 ) and S. Each R 1 , R 2 and R 3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C (1-20) alkyl, C (1-20) hydroxyalkyl, C (1-20) thioalkyl, C (1-20) alkylamino, C (1-20) alkylaminoalkyl, C (1-20) aminoalkyl, C (1-20) aminoalkoxyalkenyl, C (1-20) aminoalkoxyalkynyl, C (1-20) diaminoalkyl, C (1-20) triaminoalkyl, C (1-20) tetraaminoalkyl, C (5-15) aminotrialkoxyamino, C (1-20) alkylamido, C (1-20) alkylamidoalkyl, C (1-20) amidoalkyl, C (1-20) acetamidoalkyl, C (1-20) alkenyl, C (1-20) alkynyl, C (3-8) alkoxyl, C (1-11) alkoxyalkyl, and C (1-20) dialkoxyalkyl. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8268839-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015174132-A1 |
| priorityDate | 1998-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2759.